COVID-19 self-test for COVID-19

Phase-Based Estimates
1
Effectiveness
1
Safety
Public Health Management Corporation, Philadelphia, PA
COVID-19+1 More
COVID-19 self-test - Behavioral
Eligibility
18+
All Sexes
Eligible conditions
COVID-19

Study Summary

COVID-19 Self-Testing Through Rapid Network Distribution

See full description

Eligible Conditions

  • COVID-19
  • Covid19

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether COVID-19 self-test will improve 1 primary outcome and 7 secondary outcomes in patients with COVID-19. Measurement will happen over the course of 8 weeks.

8 weeks
Network contact test uptake
Number of contacts tested at 8 weeks
Number of positive contacts at 8 weeks
Test positivity rate per index participant
Through study completion, up to one year
Network contact test uptake, end of study
Number of contacts tested
Number of positive contacts
Proportion of first-time test takers

Trial Safety

Safety Estimate

1 of 3

Trial Design

2 Treatment Groups

Test referral distribution
Self-Test kit distribution

This trial requires 1048 total participants across 2 different treatment groups

This trial involves 2 different treatments. COVID-19 Self-test is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Self-Test kit distribution
Behavioral
Participants in the self-test arm receive multiple COVID-19 self-test kits to distribute to others in their social networks.
Test referral distribution
Behavioral
Participants in the test referral arm receive multiple COVID-19 test referral cards and text messages to distribute to others in their social networks.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, up to one year
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly through study completion, up to one year for reporting.

Who is running the study

Principal Investigator
R. G.
Prof. Robert Gross, Professor of Medicine
University of Pennsylvania

Closest Location

Public Health Management Corporation - Philadelphia, PA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
You must be at least 18 years old to gamble. show original
This organization has a working telephone number. show original
, the patient was consented for the study show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What causes covid-19?

Add answer

At present, research into the molecular causes of the Wuhan coronaviruses has largely been focused on the structural genes. A recent study from 2019 has shown that the viral RNA-dependent RNA polymerase and nucleoprotein depend on the same host cellular machinery and it is possible that the coronaviruses interact with these proteins at multiple points in viral replication. It remains to be seen whether this is a specific feature of coronaviruses, or if it offers clues or further avenues for development of new therapeutic strategies. We are in a critical moment in ensuring our populations’ and our societies’ wellbeing.

Unverified Answer

What are the signs of covid-19?

Add answer

As with other diseases, there are several clinical signs that warrant a thorough diagnostic assessment. Clinicians should also seek to examine patients' family history to confirm or exclude inherited or autoimmune disorders that might predispose to serious infection.

Unverified Answer

What is covid-19?

Add answer

Symptoms of acute cough, sore throat, conjunctivitis and conjunctive haemorrhage are described in most patient reports and thus should be considered possible non-specific diagnoses. Most patients experience flu-like symptoms like headache, myalgia, fever, fatigue and muscle tenderness. Older patients with pre-existing comorbidities exhibit more severe symptoms and a longer period of hospitalization, which could contribute to increased morbidity and mortality.

Unverified Answer

Can covid-19 be cured?

Add answer

Covid-19 can be cured. This was demonstrated in a randomized controlled trial. This suggests that future research needs to examine whether treatment for other respiratory viruses can also be effective, potentially leading to vaccines or antiviral drugs against covid-19.

Unverified Answer

What are common treatments for covid-19?

Add answer

The current situation with regard to treatment and management is unpredictable. Some treatments are being developed which might benefit patients. Many people who catch the virus do well, with only short and mild symptoms. However, some patients may present with more severe forms of illness and/or complications (e.g. pneumonia). A high priority for treatment and research continues to control the disease and prevent related complications. It is hoped, but yet to be proven, that the new treatment approaches might be helpful.

Unverified Answer

How many people get covid-19 a year in the United States?

Add answer

Approximately 26 million Americans have contracted COVID-19 at one point in time, with the median case reported as 2.0. This makes up 6.2% of American citizens.

Unverified Answer

What is the average age someone gets covid-19?

Add answer

The age of average people infected with the coronavirus is not well specified. The average adult-aged population (AAP) for England is 66.9 years old (2015). As the number of reported cases will increase, the estimated 'average age' will also increase. Based on the current data available, the average age of people infected with the coronavirus is likely to be between [52.5 years old (range: 31-77 years old)](https://www.cdc.gov/health/coronavirus2019/index_estimate.

Unverified Answer

How does covid-19 self-test work?

Add answer

The overall feasibility, accuracy and acceptance of the results for this [covid-19 self-test protocol were assessed here for first time using the STRIPeD process and its scoring approach. The new self-test protocol was found to be accurate, with low false positive rate, good feasibility in a clinical setting, acceptability of results to patients and was also found to be cost effective with low costs of the disposable self-test kits.

Unverified Answer

What is the primary cause of covid-19?

Add answer

The evidence points to the main cause of infection being a person who is infected with another virus or a yeast. It has now been recognised as a virus, but this is the first occasion on which a virus has been confirmed as the main cause of disease. The virus has evolved to be an effective, highly contagious and very dangerous pathogen and it is the first time in recorded history of a virus being the causative agent of the majority of disease. There is now a strong argument that the virus has been 'hijacked' by the immune system by the host and is now the real cause of disease in the human population.

Unverified Answer

Does covid-19 self-test improve quality of life for those with covid-19?

Add answer

Recent findings suggest that covid-19 self-testing with the covid-19 self-test in combination with a coronavirus pneumonia clinic improved quality of life in persons with covid-19. However, further studies are necessary but possible applications for the coronavirus self-test include increased access to testing, self-management, and enhanced care among persons with coronavirus.

Unverified Answer

Is covid-19 self-test safe for people?

Add answer

Results from a recent paper, a self-test with a rapid kit was highly positive in the general population tested. Results from a recent paper can complement testing for SARS-CoV-2 in suspected cases.

Unverified Answer

What are the latest developments in covid-19 self-test for therapeutic use?

Add answer

Most of the recently developed testing methods had poor analytical performance and/or clinical utility and require further improvements. In the context of a massive outbreak, rapid antibody test development is required for the diagnostic and therapeutic purpose. There is a critical need for reliable point-of-care (POCT) ELISA, rapid antibody tests for therapeutic use, in order to enable an early diagnosis and to reduce negative impact from delayed diagnosis.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for COVID-19 by sharing your contact details with the study coordinator.